Lumos Earns $507K BARDA Milestone as CLIA Waiver Opens Door to 300,000 US Sites
Lumos receives US$507,377 BARDA milestone payment following FebriDx CLIA waiver achievement
Lumos Diagnostics has received a milestone payment of US$507,377 from the Biomedical Advanced Research and Development Authority (BARDA) following its US FDA CLIA waiver clearance for FebriDx. The payment brings total funding received under the CLIA waiver study to US$2,984,571, providing non-dilutive capital to support ongoing clinical programmes including the company’s paediatric development pathway.
The funding was provided under contract number 75A50124C00051 with the US Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), through BARDA. This arrangement allows Lumos to advance its diagnostic platform without shareholder dilution, whilst benefiting from BARDA’s technical expertise in clinical study design and regulatory strategy.
The milestone payment follows the recent CLIA waiver approval for FebriDx, which represents a material commercial inflection point by expanding the test’s addressable market from specialised laboratory settings to mainstream point-of-care environments across the United States.
When big ASX news breaks, our subscribers know first
What is a CLIA waiver and why does it matter for diagnostics companies?
A CLIA waiver, granted under the Clinical Laboratory Improvement Amendments, allows diagnostic tests to be performed in settings that do not have specialised laboratory infrastructure or trained laboratory personnel. This regulatory classification fundamentally changes where and how a diagnostic product can be deployed commercially.
Tests classified as moderate-complexity require certified laboratory settings with qualified personnel, limiting their use to hospital laboratories and dedicated pathology facilities. In contrast, waived tests can be administered in primary care physician offices, urgent care clinics, pharmacies, and community health centres, provided these facilities hold a Certificate of Waiver from the Centers for Medicare & Medicaid Services.
Achieving waiver status removes significant distribution barriers for diagnostic companies. It enables point-of-care deployment at scale, transforming a product from a specialised laboratory tool into a mass-market clinical decision support solution accessible to frontline healthcare providers.
FebriDx market opportunity expands to US$1 billion-plus
The CLIA waiver expands FebriDx applicability to over 300,000 locations across the United States, unlocking access to an estimated 80 million patients per annum who present with acute respiratory infections at primary care and urgent care centres. This positions the test within a US$1.0+ billion market opportunity, approximately 15 times larger than the market available under the previous moderate-complexity classification.
Key market expansion metrics:
- Locations enabled: 300,000+ Certificate of Waiver sites
- Annual patient reach: 80 million acute respiratory infection presentations
- Market opportunity: US$1.0+ billion
- Market expansion multiple: 15x versus moderate-complexity classification
Healthcare settings now accessible for FebriDx deployment include primary care physician offices, urgent care clinics, retail health and pharmacy clinics, and community health centres. This broad distribution footprint positions the test to capture market share across the full spectrum of outpatient respiratory infection management, rather than being confined to hospital-based testing environments.
How FebriDx supports clinical decision-making
FebriDx is a rapid point-of-care test that helps healthcare professionals differentiate between bacterial and non-bacterial respiratory infections within 10 minutes, supporting more informed clinical decision-making and potentially reducing unnecessary antibiotic prescribing.
Following the CLIA waiver, no complex laboratory infrastructure or specialised training is required to administer the test. This operational simplicity supports adoption by clinicians across diverse practice settings, from solo general practice surgeries to large urgent care networks.
CEO perspective on BARDA partnership value
Doug Ward, CEO and Managing Director
“BARDA’s assistance provides not only meaningful non‑dilutive funding that extends our capacity to run critical studies, including our paediatric program, but also brings technical expertise as we advance our diagnostic solutions toward broader clinical use.”
The BARDA partnership provides dual value: financial support that extends operational runway for clinical development, and technical expertise in study design and regulatory pathways. The funding specifically supports Lumos’ paediatric programme, which aims to establish FebriDx efficacy in younger patient populations, a critical market segment for respiratory infection diagnostics.
BARDA’s involvement signals US government confidence in the FebriDx technology platform. Federal funding partnerships of this nature typically involve rigorous technical diligence and alignment with strategic health preparedness priorities, providing third-party validation of the product’s clinical utility.
Key metrics at a glance
| Metric | Value | Context |
|---|---|---|
| Milestone payment received | US$507,377 | BARDA contract |
| Total CLIA study funding | US$2,984,571 | Cumulative non-dilutive |
| US locations enabled | 300,000+ | Certificate of Waiver sites |
| Annual patient addressable | 80 million | Acute respiratory infections |
| Market opportunity | US$1.0+ billion | 15x prior classification |
The next major ASX story will hit our subscribers first
Next steps for Lumos and FebriDx commercialisation
With the CLIA waiver secured and BARDA funding in hand, Lumos enters an execution phase focused on converting the expanded addressable market into commercial revenue. Commercialisation activities can now target the full spectrum of Certificate of Waiver sites across the United States, supported by the product’s simplified workflow and point-of-care positioning.
Ongoing clinical studies, including the paediatric programme funded through the BARDA contract, aim to broaden the clinical evidence base supporting FebriDx adoption. Paediatric clearance would further expand the test’s utility in primary care and urgent care settings, where children represent a significant proportion of acute respiratory infection presentations.
Investor focus shifts to commercial execution metrics: distribution partnerships, site activation rates, test volume growth, and revenue conversion from the US$1 billion-plus market opportunity now accessible through the waiver pathway.
Want the Next Healthcare Breakout in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to receive real-time alerts the moment market-moving announcements hit the ASX.